Nanoform Finland (FRA:4YL) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4YL Nanoform Finland PLC FRA:4YL
63 GF Score
Price €0.90
GF Value €1.72
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Nanoform Finland Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Nanoform Finland is: High Risk: High uncertainty.

Nanoform Finland  (FRA:4YL) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Nanoform Finland Risk Assessment Related Terms

FRA:4YL vs VRTX, REGN, RVMD: Risk Assessment Comparison

For the Biotechnology subindustry, Nanoform Finland's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanoform Finland Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoform Finland's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Nanoform Finland's Risk Assessment falls into.


FRA:4YL
63GF Score
Nanoform Finland PLC FRA:4YL
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nanoform Finland (FRA:4YL) Overvalued in 2026?

Based on GuruFocus' analysis, Nanoform Finland stock appears to be undervalued. The current stock price of €0.90 is trading 47.9% below its estimated GF Value™ of €1.72. GuruFocus considers Nanoform Finland to be Possible Value Trap.

Key valuation signals for FRA:4YL:

  • Risk Assessment:
  • GF Value™: €1.72 vs. price of €0.90 (47.9% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the FRA:4YL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanoform Finland Business Description

Other Exchanges NANOFS:SwedenNANOFH:Finland
Address Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
63GF Score

Get the complete analysis for FRA:4YL

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.90
Price
€1.72
GF Value